# Safety, Efficacy and Pharmacokinetic Behavior of Leuprolide Injectable Emulsion for Premenopausal Breast Cancer Subjects.

> **NCT06449027** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Changchun GeneScience Pharmaceutical Co., Ltd.** · enrollment: 211 (actual)

## Conditions studied

- Breast Cancer Subjects

## Interventions

- **DRUG:** T Leuprolide Injectable Emulsion
- **DRUG:** Leuprorelin Acetate Microspheres for Injection

## Key facts

- **NCT ID:** NCT06449027
- **Lead sponsor:** Changchun GeneScience Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-08-21
- **Primary completion:** 2025-11
- **Final completion:** 2026-03
- **Target enrollment:** 211 (ACTUAL)
- **Last updated:** 2025-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06449027

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06449027, "Safety, Efficacy and Pharmacokinetic Behavior of Leuprolide Injectable Emulsion for Premenopausal Breast Cancer Subjects.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06449027. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*